ATRYS HEALTH, S.A. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.88 EUR | -0.35% |
|
-2.37% | -21.53% |
| Mar. 26 | Atrys Health, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Atrys Health, S.A. announced that it has received ?13.3 million in funding | CI |
| Sales 2024 * | 223M 239M | Sales 2025 * | 240M 257M | Capitalization | 219M 235M |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 | Net income 2025 * | 8M 8.58M | EV / Sales 2024 * | 1.68 x |
| Net Debt 2024 * | 155M 167M | Net Debt 2025 * | 121M 130M | EV / Sales 2025 * | 1.42 x |
| P/E ratio 2024 * |
-67
x | P/E ratio 2025 * |
25.1
x | Employees | 1,865 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.57% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.35% | ||
| 1 week | -2.37% | ||
| Current month | -6.19% | ||
| 1 month | -8.28% | ||
| 3 months | -20.00% | ||
| 6 months | -20.00% | ||
| Current year | -21.53% |
1 week
2.87
2.95
1 month
2.873.18
Current year
2.773.85
1 year
2.775.90
3 years
2.7711.25
5 years
2.7711.25
10 years
1.3911.25
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 07-06-12 | |
| Director of Finance/CFO | - | 15-07-31 | |
| Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 48 | 16-01-31 | |
| Director/Board Member | 69 | - | |
| Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 2.88 | -0.35% | 2 511 |
| 24-04-25 | 2.89 | +0.35% | 114,450 |
| 24-04-24 | 2.88 | -2.37% | 18,085 |
| 24-04-23 | 2.95 | +0.34% | 2,842 |
| 24-04-22 | 2.94 | -0.34% | 119,987 |
Delayed Quote BME, April 26, 2024 at 03:08 am EDT
More quotes
Atrys Health SA, formerly Europath Biosciences SL, is Spain-based company primarily engaged in the predictive and personalized oncology therapies. It operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies. It has four areas of activity: Laboratory, Telemedicine, Radiotherapy, as well as Research and Development (R&D). The Company has its diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid, Spain.
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.89
EUR
Average target price
6.61
EUR
Spread / Average Target
+128.72%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.53% | 235M | |
| -14.73% | 84.87B | |
| +16.05% | 83.08B | |
| +10.92% | 29.4B | |
| -12.73% | 16.72B | |
| -3.03% | 16.4B | |
| -1.78% | 15.04B | |
| -0.55% | 11.88B | |
| -31.05% | 11.86B | |
| -4.14% | 11.88B |
- Stock Market
- Equities
- ATRY Stock
